ALXOALX Oncology Inc.Signing up patients
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Breast Cancer, Metastatic
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.9
2 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 2
- Patients
- 120 (planned)
- Started
- Dec 10, 2025
- Main results expected
- Dec 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
Measured over: Approximately 6 months after the last participant is enrolled
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT07007559 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC